Moderna: Analyzing The January Rally And The Road Ahead (Rating Upgrade) [Seeking Alpha]
Moderna, Inc. (MRNA)
Last moderna, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
marinabio.com/investor-relations
Company Research
Source: Seeking Alpha
MRNA's updated five-year phase 2b data for Intismeran autogene showed a 49% reduction in death or recurrence in melanoma, showing a benefit of MRNA's cancer vaccine remains at five years. A 2026 readout from a phase 3 trial of intismeran autogene in melanoma is possible, as is a 2026 readout from a phase 2 trial in renal cell carcinoma. MRNA's preliminary 2025 financials include ~$1.9B in revenue and GAAP operating expenses of $5B-$5.2B, with Q4 '25 earnings set for February 13, 2026. Oliver Rossi/DigitalVision via Getty Images Moderna, Inc. ( MRNA ) has made a strong start to 2026 with a 59% rally year-to-date helping the stock break out of a previous 2025 trading range. When I last wrote about MRNA in October, I rated This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it express
Show less
Read more
Impact Snapshot
Event Time:
MRNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRNA alerts
High impacting Moderna, Inc. news events
Weekly update
A roundup of the hottest topics
MRNA
News
- Defiance Launches MRNX: The First Daily 2X Long ETF for Moderna, Inc.GlobeNewswire
- Moderna (NASDAQ:MRNA) had its "underperform" rating reaffirmed by analysts at Leerink Partners.MarketBeat
- Moderna (NASDAQ:MRNA) had its "hold" rating reaffirmed by analysts at TD Cowen.MarketBeat
- Moderna (NASDAQ:MRNA) is now covered by analysts at Barclays PLC. They set an "equal weight" rating and a $25.00 price target on the stock.MarketBeat
- Moderna (MRNA) Touches 52-Week High on Strong Clinical Results [Yahoo! Finance]Yahoo! Finance
MRNA
Earnings
- 11/6/25 - Beat
MRNA
Sec Filings
- 2/6/26 - Form SCHEDULE
- 2/5/26 - Form SCHEDULE
- 1/12/26 - Form 8-K
- MRNA's page on the SEC website